March 7, 2019
Forendo plans phase 1b study of endometriosis treatment inhibitor in summer
Forendo Pharma has completed Phase 1a study of FOR-6219, an HSD17B1 inhibitor for the treatment of endometriosis, with single and multiple ascending oral doses of FOR-6219 in 36 healthy postmenopausal women.